Log In
Print this Print this

CAG gapmers

  Manage Alerts
Collapse Summary General Information
Company Ionis Pharmaceuticals Inc.
DescriptionChimeric antisense oligonucleotides containing modified nucleic acid residues that induce RNase H-mediated degradation of CUG repeats
Molecular Target
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPreclinical
Standard IndicationMyotonic dystrophy type 1 (DM1)
Indication DetailsTreat myotonic dystrophy type 1 (DM1)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today